<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	The study did not use antibodies	n/a
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	The study did not use cell lines	n/a
Provide accession number in repository OR		, a
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of	The study did not use primary cultures	n/a
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	The study did not use laboratory animals	n/a
genetic modification status. Provide accession	The study did not use laboratory animals	11/ 4
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the	The study did not use animals observed or captured	n/a
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number	The study did not use model organisms	n/a
in repository (where relevant) OR RRID		
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	The study did not use plants	n/a
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique	The study did not use microbes	n/a
accession number if available, and source		
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Ethical Committee of the Medical Chamber in Cracow	
equivalent committee(s), provide reference number	has waived the approval because of the retrospective	
for approval.	character of the study	
Provide statement confirming informed consent	Written informed consent has been waived for the	
obtained from study participants.	retrospective analysis of the historical hospital records	

<u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	The study is not a clinical trial	n/a
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	The study did not involve laboratory analysis	n/a
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	Not preformed, due to the retrospective character of	n/a
Randomisation	Not preformed, due to the retrospective character of	n/a
Blinding	Not preformed, due to the retrospective character of	n/a
Inclusion/exclusion criteria	Inclusion criteria were as follows: age 18-90 years,	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	The study was non-experimental	n/a
Define whether data describe technical or biological replicates	The study was non-experinental	n/a
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Ethical Committee of the Medical Chamber in Cracow has waived the approval because of the retrospective character of the study.	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	The study did not use experimental animals	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Tissue specimens were obtained and processed for the treatment purposes at the time of surgical procedure	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	The study is not a subject to dual use research of concern	n/a

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	No, due to the retrospective character of the study	n/a
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Statistical 13.0 software (StatSoft, Tulsa, Oklahoma, USA) was used for statistical analysis. Because of failure of assumptions (normality), the Spearman's rank correlation coefficient was used to assess correlations of analysed variables. Significance of differences between groups was verified using the Kruskal-Wallis test. Post-hoc tests were used for particular comparisons. For all tests, the p value < 0.05 was considered statistically significant.	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	The dataset is available on request in the Institution	
If data are publicly available, provide accession number in repository or DOI or URL.	The data are not publicly available	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	The data are not publicly available	n/a
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	No code or software was generated by the study	n/a
If code is publicly available, provide accession number in repository, or DOI or URL.	No code or software was generated by the study	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: https://dx.doi.org/10.21037/tcr-23-798